SOLENO THERAPEUT. DL-001 (F:6XC) — Market Cap & Net Worth
Market Cap & Net Worth: SOLENO THERAPEUT. DL-001 (6XC)
SOLENO THERAPEUT. DL-001 (F:6XC) has a market capitalization of $2.04 Billion (€1.75 Billion) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #6169 globally and #926 in its home market, demonstrating a -0.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SOLENO THERAPEUT. DL-001's stock price €44.51 by its total outstanding shares 53710025 (53.71 Million).
SOLENO THERAPEUT. DL-001 Market Cap History: 2019 to 2026
SOLENO THERAPEUT. DL-001's market capitalization history from 2019 to 2026. Data shows growth from $148.19 Million to $2.79 Billion (60.57% CAGR).
SOLENO THERAPEUT. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SOLENO THERAPEUT. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6XC by Market Capitalization
Companies near SOLENO THERAPEUT. DL-001 in the global market cap rankings as of May 4, 2026.
Key companies related to SOLENO THERAPEUT. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
SOLENO THERAPEUT. DL-001 Historical Marketcap From 2019 to 2026
Between 2019 and today, SOLENO THERAPEUT. DL-001's market cap moved from $148.19 Million to $ 2.79 Billion, with a yearly change of 60.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.79 Billion | +12.91% |
| 2025 | €2.48 Billion | -5.96% |
| 2024 | €2.63 Billion | +101.54% |
| 2023 | €1.31 Billion | +1068.54% |
| 2022 | €111.77 Million | +358.76% |
| 2021 | €24.36 Million | -74.13% |
| 2020 | €94.19 Million | -36.44% |
| 2019 | €148.19 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of SOLENO THERAPEUT. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.04 Billion USD |
| MoneyControl | $2.04 Billion USD |
| MarketWatch | $2.04 Billion USD |
| marketcap.company | $2.04 Billion USD |
| Reuters | $2.04 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia… Read more